Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment

Study Overview
=================
Brief Summary
-----------------
Sarcopenia is associated with the prognosis of HCC and cholangiocarcinoma. But there has been rare study focusing on the effect of sarcopenia on the prognosis of HCC treated with lenvatinib and anti-PD1.

Detailed Description
-----------------
By tracking the short-term and long-term results of HCC patients treated with lenvatinib and anti-PD1,the difference of short-term results between patients with sarcopenia and patients without sarcopenia was analyzed, and the correlation between sarcopenia and short-term and long-term results of patients after systemic treatment was explored, so as to improve people's awareness of sarcopenia and pay attention to its prevention and treatment.All implementation details are based on the newest EWGSOP definition. The investigators consecutively admitted patients the questionnaire and evaluated the assessment of muscle strength (grip strength test and chair stand test), muscle quantity (L3 plane total skeletal muscle area) and physical performance (gait test) following the F-A-C-S approach, to confirm patients with sarcopenia accurately. And by tracking the short-term and long-term outcomes, the differences were analyzed and the relationship between sarcopenia and prognosis of systemic treatment was explored.

Official Title
-----------------
The Effect of Sarcopenia on the Efficacy and Prognosis of HCC Treated With Lenvatinib and Anti-PD-1 Treatment

Conditions
-----------------
Liver Cancer, Sarcopenia

Intervention / Treatment
-----------------
* Diagnostic Test: gait speed; ct scan; grip strength and chair stand test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with clinical diagnosis of liver cancer No cancer other than liver cancer has been diagnosed Age ≥18 years Exclusion Criteria: Patients who could not complete the standard tests and questionnaires Patients received other therapies Patients who had other causes of muscle weakness (injury, fracture, stroke, etc.) Patients who missing CT data or CT scan did not reach the level of the third lumbar vertebra (L3)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with sarcopenia<br> | Diagnostic Test: gait speed; ct scan; grip strength and chair stand test<br>* The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.<br>|
| patients without sarcopenia<br> | Diagnostic Test: gait speed; ct scan; grip strength and chair stand test<br>* The chair stand test was administered, and the time required for the patient to stand five times from a sitting position without using the arms was measured. CT scan was to scan the patient's third lumbar level. For the gait speed test, the time that patients spent walking 8 meters on a flat indoor floor at usual walking speed was measured.Grip strength test:the dominant hand and the nondominant hand were measured twice intermittently (kg), and the average value of 4 values was obtained.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Short-term results | Post-treatment complications | 3 months | 
| Long-term results | Overall survival; Progression free survival | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver cancer, sarcopenia, lenvatinib, immune therapy, prognosis